Zusammenfassung
Osteoimmunologie definiert einen Forschungsbereich mit dem Schwerpunkt der Kommunikation zwischen dem Immunsystem und dem muskuloskeletalen System. Wir stehen erst am Beginn, die grundlegenden Prinzipien dieser zellulären Kommunikation zu verstehen. Es scheint, dass nahezu alle Immunzellen in der Lage sind, mit Osteoblasten, Osteoklasten und deren Vorläuferzellen zu kommunizieren – und vice versa. Osteoporose, rheumatoide Arthritis und Parodontitis zählen zu den Erkrankungen, deren Pathogenese im Zusammenhang mit der Osteoimmunologie steht, insgesamt Krankheiten mit hohem Einfluss auf die Lebensqualität und mit zunehmender sozioökonomischer Bedeutung. Zum besseren Verständnis der Pathogenese müssen die Hauptwege der Kommunikation zwischen dem Immunsystem und dem muskuloskeletalen System erkannt werden. Unser bisheriges Verständnis schaffte bereits die wissenschaftliche Grundlage für die Entwicklung gezielter Therapien. Allerdings sind weitere Entschlüsselungen dieser Kommunikationen auf zellulärer und molekularer Ebene notwendig und bleiben eine Herausforderung.
Summary
Osteoimmunology is defined as the research area focusing on the crosstalk between the immune system and the muskoskeletal system. After nearly a decade of research, we are now beginning to understand the basic principles of this crosstalk. It seems that almost all immune cells are capable of communicating with osteoblasts, osteoclasts, and their respective progenitors – and vice versa. Diseases that fall into the category of osteoimmunology including osteoporosis, rheumatoid arthritis, and periodontal disease are of particular significance considering their implications in quality of life, their increased incidence in the population, and socioeconomic issues. To better understand the underlying pathogenesis, the main pathways of the crosstalk between the immune system and the muskoskeletal system need to be uncovered. Our current understanding has already provided the scientific basis for the development of targeted therapies. However, the challenge of future studies is to further decipher this crosstalk at cellular and molecular levels.
References
Arron JR, Choi Y. Bone versus immune system. Nature, 408: 535–536, 2000
Rothe A, Power BE, Hudson PJ. Therapeutic advances in rheumatology with the use of recombinant proteins. Nat Clin Pract Rheumatol, 4: 605–614, 2008
Sipos W, Pietschmann P, Rauner M. Strategies for novel therapeutic approaches targeting cytokines and signaling pathways of osteoclasto- and osteoblastogenesis in the fight against immune-mediated bone and joint diseases. Curr Med Chem, 15: 127–136, 2008
Takayanagi H. Osteoimmunology and the effects of the immune system on bone. Nat Rev Rheumatol, 5: 667–676, 2009
Schett G. Osteoimmunology in rheumatic diseases. Arthritis Res Ther, 11: 210, 2009
Lorenzo J, Horowitz M, Choi Y. Osteoimmunology: interactions of the bone and immune system. Endocr Rev, 29: 403–440, 2008
Rauner M, Sipos W, Pietschmann P. Osteoimmunology. Int Arch Allergy Immunol, 143: 31–48, 2007
Takayanagi H. Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol, 7:292–304, 2007
Riggs BL, Parfitt AM. Drugs used to treat osteoporosis: the critical need for a uniform nomenclature based on their action on bone remodeling. J Bone Miner Res, 20: 177–184, 2005
Riggs BL, Khosla S, Melton LJ 3rd. Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev, 23: 279–302, 2002
Pacifici R. Estrogen deficiency, T cells and bone loss. Cell Immunol, 252: 68–80, 2008
McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol, 7: 429–442, 2007
Nanci A, Bosshardt DD. Structure of periodontal tissues in health and disease. Periodontol 2000, 40: 11–28, 2006
de Pablo P, Chapple IL, Buckley CD, Dietrich T. Periodontitis in systemic rheumatic diseases. Nat Rev Rheumatol, 5: 218–224, 2009
Graat-Verboom L, Wouters EF, Smeenk FW, Van den Borne BE, Lunde R, Spruit MA. Current status of research on osteoporosis in COPD: a systematic review. Eur Respir J, 34: 209–218, 2009
Tilg H, Moschen AR, Kaser A, Pines A, Dotan I. Gut, inflammation and osteoporosis: basic and clinical concepts. Gut, 57: 684–694, 2008
Schett G, Kiechl S, Weger S, Pederiva A, Mayr A, Petrangeli M, Oberhollenzer F, Lorenzini R, Redlich K, Axmann R, Zwerina J, Willeit J. High-sensitivity C-reactive protein and risk of nontraumatic fractures in the Bruneck study. Arch Intern Med, 166: 2495–2501, 2006
Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer, 2: 584–593, 2002
Roodman GD. Mechanisms of bone metastasis. N Engl J Med, 350: 1655–1664, 2004
Medzhitov R, Janeway C Jr. Innate immunity. N Engl J Med, 343: 338–344, 2000
Delves PJ, Roitt IM. The immune system. First of two parts. N Engl J Med, 343: 37–49, 2000
Delves PJ, Roitt IM. The immune system. Second of two parts. N Engl J Med, 343: 108–117, 2000
Zaidi M. Skeletal remodeling in health and disease. Nat Med, 13:791–801, 2007
Eriksen EF, Eghbali-Fatourechi GZ, Khosla S. Remodeling and vascular spaces in bone. J Bone Miner Res, 22: 1–6, 2007
Kearns AE, Khosla S, Kostenuik PJ. Receptor activator of nuclear factor kappa B ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev, 29: 155–192, 2008
Leibbrandt A, Penninger JM. RANK/RANKL: regulators of immune responses and bone physiology. Ann NY Acad Sci, 1143: 123–150, 2008
Zwerina J, Redlich K, Polzer K, Joosten L, Kronke G, Distler J, Hess A, Pundt N, Pap T, Hoffmann O, Gasser J, Scheinecker C, Smolen JS, van den Berg W, Schett G. TNF-induced structural joint damage is mediated by IL-1. Proc Natl Acad Sci USA, 104:11742–11747, 2007
Polzer K, Joosten L, Gasser J, Distler JH, Ruiz G, Baum W, Redlich K, Bobacz K, Smolen JS, van den Berg W, Schett G, Zwerina J. IL-1 is essential for systemic inflammatory bone loss. Ann Rheum Dis, 69(1): 284–290, 2010
Sato K, Suematsu A, Okamoto K, Yamaguchi A, Morishita Y, Kadono Y, Tanaka S, Kodama T, Akira S, Iwakura Y, Cua DJ, Takayanagi H. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med, 203: 2673–2682, 2006
Nakae S, Nambu A, Sudo K, Iwakura Y. Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J Immunol, 171: 6173–6177, 2003
Pene J, Chevalier S, Preisser L, Venereau E, Guilleux MH, Ghannam S, Moles JP, Danger Y, Ravon E, Lesaux S, Yssel H, Gascan H. Chronically inflamed human tissues are infiltrated by highly differentiated Th17 lymphocytes. J Immunol, 180: 7423–7430, 2008
Gaffen SL, Hajishengallis G. A new inflammatory cytokine on the block: re-thinking periodontal disease and the Th1/Th2 paradigm in the context of Th17 cells and IL-17. J Dent Res, 87: 817–828, 2008
Chabaud M, Durand JM, Buchs N, Fossiez F, Page G, Frappart L, Miossec P. Human interleukin-17: a T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum, 42: 963–970, 1999
Vernal R, Dutzan N, Chaparro A, Puente J, Antonieta Valenzuela M, Gamonal J. Levels of interleukin-17 in gingival crevicular fluid and in supernatants of cellular cultures of gingival tissue from patients with chronic periodontitis. J Clin Periodontol, 32: 383–389, 2005
Roggia C, Gao Y, Cenci S, Weitzmann MN, Toraldo G, Isaia G, Pacifici R. Up-regulation of TNF-producing T cells in the bone marrow: a key mechanism by which estrogen deficiency induces bone loss in vivo. Proc Natl Acad Sci USA, 98: 13960–13965, 2001
Goswami J, Hernandez-Santos N, Zuniga LA, Gaffen SL. A bone-protective role for IL-17 receptor signaling in ovariectomy-induced bone loss. Eur J Immunol, 39: 2831–2839, 2009
Sakaguchi S, Ono M, Setoguchi R, Yagi H, Hori S, Fehervari Z, Shimizu J, Takahashi T, Nomura T. Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev, 212: 8–27, 2006
Axmann R, Herman S, Zaiss M, Franz S, Polzer K, Zwerina J, Herrmann M, Smolen J, Schett G. CTLA-4 directly inhibits osteoclast formation. Ann Rheum Dis, 67: 1603–1609, 2008
Zaiss MM, Axmann R, Zwerina J, Polzer K, Guckel E, Skapenko A, Schulze-Koops H, Horwood N, Cope A, Schett G. Treg cells suppress osteoclast formation: a new link between the immune system and bone. Arthritis Rheum, 56: 4104–4112, 2007
Isaacs JD. Therapeutic agents for patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor-alpha antagonists. Expert Opin Biol Ther, 9: 1463–1475, 2009
Eghbali-Fatourechi G, Khosla S, Sanyal A, Boyle WJ, Lacey DL, Riggs BL. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest, 111: 1221–1230, 2003
Li Y, Toraldo G, Li A, Yang X, Zhang H, Qian WP, Weitzmann MN. B cells and T cells are critical for the preservation of bone homeostasis and attainment of peak bone mass in vivo. Blood, 109: 3839–3848, 2007
Diarra D, Stolina M, Polzer K, Zwerina J, Ominsky MS, Dwyer D, Korb A, Smolen J, Hoffmann M, Scheinecker C, van der Heide D, Landewe R, Lacey D, Richards WG, Schett G. Dickkopf-1 is a master regulator of joint remodeling. Nat Med, 13: 156–163, 2007
Uderhardt S, Diarra D, Katzenbeisser J, David JP, Zwerina J, Richards WG, Kronke G, Schett G. Blockade of Dickkopf-1 induces fusion of sacroiliac joints. Ann Rheum Dis, 69(3): 592–597, 2010
Pinzone JJ, Hall BM, Thudi NK, Vonau M, Qiang YW, Rosol TJ, Shaughnessy JD Jr. The role of Dickkopf-1 in bone development, homeostasis, and disease. Blood, 113: 517–525, 2009
Colburn NT, Zaal KJ, Wang F, Tuan RS. A role for gamma/delta T cells in a mouse model of fracture healing. Arthritis Rheum, 60: 1694–1703, 2009
Visnjic D, Kalajzic Z, Rowe DW, Katavic V, Lorenzo J, Aguila HL. Hematopoiesis is severely altered in mice with an induced osteoblast deficiency. Blood, 103: 3258–3264, 2004
Testa NG, Dexter TM. The biology of long-term bone marrow cultures and its application to bone marrow transplantation. Curr Opin Oncol, 3: 272–278, 1991
Calvi LM, Adams GB, Weibrecht KW, Weber JM, Olson DP, Knight MC, Martin RP, Schipani E, Divieti P, Bringhurst FR, Milner LA, Kronenberg HM, Scadden DT. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature, 425: 841–846, 2003
Zhang J, Niu C, Ye L, Huang H, He X, Tong WG, Ross J, Haug J, Johnson T, Feng JQ, Harris S, Wiedemann LM, Mishina Y, Li L. Identification of the haematopoietic stem cell niche and control of the niche size. Nature, 425: 836–841, 2003
Xie Y, Yin T, Wiegraebe W, He XC, Miller D, Stark D, Perko K, Alexander R, Schwartz J, Grindley JC, Park J, Haug JS, Wunderlich JP, Li H, Zhang S, Johnson T, Feldman RA, Li L. Detection of functional haematopoietic stem cell niche using real-time imaging. Nature, 457: 97–101, 2009
Ballen K. Targeting the stem cell niche: squeezing blood from bones. Bone Marrow Transplant, 39: 655–660, 2007
Onoe Y, Miyaura C, Ito M, Ohta H, Nozawa S, Suda T. Comparative effects of estrogen and raloxifene on B lymphopoiesis and bone loss induced by sex steroid deficiency in mice. J Bone Miner Res, 15: 541–549, 2000
Hayer S, Polzer K, Brandl A, Zwerina J, Kireva T, Smolen JS, Schett G. B-cell infiltrates induce endosteal bone formation in inflammatory arthritis. J Bone Miner Res, 23: 1650–1660, 2008
Kawai T, Matsuyama T, Hosokawa Y, Makihira S, Seki M, Karimbux NY, Goncalves RB, Valverde P, Dibart S, Li YP, Miranda LA, Ernst CW, Izumi Y, Taubman MA. B and T lymphocytes are the primary sources of RANKL in the bone resorptive lesion of periodontal disease. Am J Pathol, 169: 987–998, 2006
Yamaguchi M, Ukai T, Kaneko T, Yoshinaga M, Yokoyama M, Ozaki Y, Hara Y. T cells are able to promote lipopolysaccharide-induced bone resorption in mice in the absence of B cells. J Periodontal Res, 43: 549–555, 2008
Horowitz MC, Xi Y, Pflugh DL, Hesslein DG, Schatz DG, Lorenzo JA, Bothwell AL. Pax5-deficient mice exhibit early onset osteopenia with increased osteoclast progenitors. J Immunol, 173: 6583–6591, 2004
Rivollier A, Mazzorana M, Tebib J, Piperno M, Aitsiselmi T, Rabourdin-Combe C, Jurdic P, Servet-Delprat C. Immature dendritic cell transdifferentiation into osteoclasts: a novel pathway sustained by the rheumatoid arthritis microenvironment. Blood, 104: 4029–4037, 2004
Alnaeeli M, Park J, Mahamed D, Penninger JM, Teng YT. Dendritic cells at the osteo-immune interface: implications for inflammation-induced bone loss. J Bone Miner Res, 22: 775–780, 2007
Page G, Miossec P. RANK and RANKL expression as markers of dendritic cell-T cell interactions in paired samples of rheumatoid synovium and lymph nodes. Arthritis Rheum, 52: 2307–2312, 2005
Cutler CW, Teng YT. Oral mucosal dendritic cells and periodontitis: many sides of the same coin with new twists. Periodontol 2000, 45:35–50, 2007
Leung BP, Conacher M, Hunter D, McInnes IB, Liew FY, Brewer JM. A novel dendritic cell-induced model of erosive inflammatory arthritis: distinct roles for dendritic cells in T cell activation and induction of local inflammation. J Immunol, 169: 7071–7077, 2002
da Costa CE, Annels NE, Faaij CM, Forsyth RG, Hogendoorn PC, Egeler RM. Presence of osteoclast-like multinucleated giant cells in the bone and nonostotic lesions of Langerhans cell histiocytosis. J Exp Med, 201: 687–693, 2005
Nathan C. Neutrophils and immunity: challenges and opportunities. Nat Rev Immunol, 6: 173–182, 2006
Lisignoli G, Toneguzzi S, Pozzi C, Piacentini A, Riccio M, Ferruzzi A, Gualtieri G, Facchini A. Proinflammatory cytokines and chemokine production and expression by human osteoblasts isolated from patients with rheumatoid arthritis and osteoarthritis. J Rheumatol, 26: 791–799, 1999
Bouchard L, Naccache PH, Poubelle PE. Promotion of neutrophil adherence to human osteoblasts by microcrystals and f-Met-Leu-Phe. Biochem Biophys Res Commun, 296: 759–764, 2002
Chung R, Cool JC, Scherer MA, Foster BK, Xian CJ. Roles of neutrophil-mediated inflammatory response in the bony repair of injured growth plate cartilage in young rats. J Leukoc Biol, 80: 1272–1280, 2006
Chakravarti A, Raquil MA, Tessier P, Poubelle PE. Surface RANKL of Toll-like receptor 4-stimulated human neutrophils activates osteoclastic bone resorption. Blood, 114: 1633–1644, 2009
Nigrovic PA, Lee DM. Mast cells in inflammatory arthritis. Arthritis Res Ther, 7: 1–11, 2005
Chiappetta N, Gruber B. The role of mast cells in osteoporosis. Semin Arthritis Rheum, 36: 32–36, 2006
Silberstein R, Melnick M, Greenberg G, Minkin C. Bone remodeling in W/Wv mast cell deficient mice. Bone, 12: 227–236, 1991
Fitzpatrick LA, Buzas E, Gagne TJ, Nagy A, Horvath C, Ferencz V, Mester A, Kari B, Ruan M, Falus A, Barsony J. Targeted deletion of histidine decarboxylase gene in mice increases bone formation and protects against ovariectomy-induced bone loss. Proc Natl Acad Sci USA, 100: 6027–6032, 2003
Blair HC, Dong SS, Julian BA. Expression of stem cell factor by osteoblasts in normal and hyperparathyroid bone: relation to ectopic mast cell differentiation. Virchows Arch, 435: 50–57, 1999
Lee DM, Friend DS, Gurish MF, Benoist C, Mathis D, Brenner MB. Mast cells: a cellular link between autoantibodies and inflammatory arthritis. Science, 297: 1689–1692, 2002
Kacena MA, Ciovacco WA. Megakaryocyte-bone cell interactions. Adv Exp Med Biol, 658: 31–41, 2010
Kacena MA, Shivdasani RA, Wilson K, Xi Y, Troiano N, Nazarian A, Gundberg CM, Bouxsein ML, Lorenzo JA, Horowitz MC. Megakaryocyte-osteoblast interaction revealed in mice deficient in transcription factors GATA-1 and NF-E2. J Bone Miner Res, 19: 652–660, 2004
Kacena MA, Gundberg CM, Nelson T, Horowitz MC. Loss of the transcription factor p45 NF-E2 results in a developmental arrest of megakaryocyte differentiation and the onset of a high bone mass phenotype. Bone, 36: 215–223, 2005
Ciovacco WA, Goldberg CG, Taylor AF, Lemieux JM, Horowitz MC, Donahue HJ, Kacena MA. The role of gap junctions in megakaryocyte-mediated osteoblast proliferation and differentiation. Bone, 44: 80–86, 2009
Bord S, Frith E, Ireland DC, Scott MA, Craig JI, Compston JE. Megakaryocytes modulate osteoblast synthesis of type-l collagen, osteoprotegerin, and RANKL. Bone, 36: 812–819, 2005
Beeton CA, Bord S, Ireland D, Compston JE. Osteoclast formation and bone resorption are inhibited by megakaryocytes. Bone, 39: 985–990, 2006
Kacena MA, Nelson T, Clough ME, Lee SK, Lorenzo JA, Gundberg CM, Horowitz MC. Megakaryocyte-mediated inhibition of osteoclast development. Bone, 39: 991–999, 2006
Chagraoui H, Sabri S, Capron C, Villeval JL, Vainchenker W, Wendling F. Expression of osteoprotegerin mRNA and protein in murine megakaryocytes. Exp Hematol, 31: 1081–1088, 2003
Gruber R, Karreth F, Kandler B, Fuerst G, Rot A, Fischer MB, Watzek G. Platelet-released supernatants increase migration and proliferation, and decrease osteogenic differentiation of bone marrow-derived mesenchymal progenitor cells under in vitro conditions. Platelets, 15: 29–35, 2004
Gruber R, Karreth F, Fischer MB, Watzek G. Platelet-released supernatants stimulate formation of osteoclast-like cells through a prostaglandin/RANKL-dependent mechanism. Bone, 30: 726–732, 2002
Endresen GK, Forre O. Human platelets in synovial fluid. A focus on the effects of growth factors on the inflammatory responses in rheumatoid arthritis. Clin Exp Rheumatol, 10: 181–187, 1992
Steinberg AD, Alves ME, Lipowski J, Lebreton GC. Platelet association with gingival tissue inflammation. J Periodontol, 66: 860–863, 1995
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Gruber, R. Cell biology of osteoimmunology. Wien Med Wochenschr 160, 438–445 (2010). https://doi.org/10.1007/s10354-010-0809-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10354-010-0809-y
Schlüsselwörter
- Osteoimmunologie
- Osteoporose
- Rheumatoide Arthritis
- Parodontitis
- Knochenumbau
- Entzündungen
- Osteoklast
- Leukozyt